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Lysophosphatidic acid (LPA) is a bioactive phospholipid that aﬀects various biological functions, such as cell proliferation,
migration, survival, wound healing, and tumor invasion through LPA receptors. Previously, we reported that LPA induces A431
colony dispersal, accompanied by disruption of cell-cell contacts and cell migration. However, it remains unclear how LPA aﬀects
cell migration and gene expression during A431 colony dispersal. In this paper, we performed cDNA microarray analysis to
investigate this question by comparing gene expression between untreated and LPA-treated A431 cells. Interestingly, these results
revealed that LPA treatment upregulates several TGF-β1 target genes, including laminin-332 (Ln-332) components (α3, β3, and
γ2 chains). Western blot analysis also showed that LPA increased phosphorylation of Smad2, an event that is carried out by TGF-
β1 interactions. Among the genes upregulated, we further addressed the role of Ln-332. Real-time PCR analysis conﬁrmed the
transcriptional upregulation of all α3, β3, and γ2 chains of Ln-332 by LPA, corresponding to the protein level increases revealed by
western blot. Further, the addition of anti-Ln-332 antibody prevented LPA-treated A431 colonies from dispersing. Taken together,
our results suggest that LPA-induced Ln-332 plays a signiﬁcant role in migration of individual cells from A431 colonies.
1.Introduction
Lysophosphatidic acid (LPA) is a phospholipid growth factor
involved in a variety of physiological functions such as
cellularproliferation,diﬀerentiation,migration,andsurvival
[1, 2]. In addition, it has also been shown to have a
role in pathological conditions like wound healing and
tumorigenesis [3]. LPA is naturally produced by many cells,
including platelets, ﬁbroblasts, and adipocytes; therefore,
body ﬂuids like serum, saliva, and other follicular ﬂuids
are a rich source of LPA [4–7]. It is well established that
LPA signals various events through its G protein-coupled
receptors (GPCR), namely, LPA-1-4 [8].
During tumorigenesis, LPA is reportedly involved in
both cell migration and invasion [9–12]. Many reports have
shown that LPA plays an important role particularly in ovar-
ian cancer, aﬀecting various aspects of cancer development,
including cellular proliferation, angiogenesis, migration, and
survival [13, 14]. It has also been shown that increased
levels of LPA are found in the plasma of ovarian cancer
patients, compared to disease-free subjects [15]. Normal
ovarian epithelial cells produce trace amounts of LPA,
whereas ovarian cancer cells produce LPA in large amounts
[16]. Similarly, in prostate cancer, LPA is reported to
induce proliferation and survival of androgen-independent
prostate cancer cells [17, 18]. In lung cancer, LPA has
been shown to induce cellular migration [19]. LPA levels
are also signiﬁcantly increased in patients with myeloma,
endometrialcancer,andcervicalcancer[20,21].Autotaxin,a
soluble exoenzyme upregulated in cancer cells that increases
cell invasion, has been found to stimulate proliferation
and motility of cancer cells through LPA production [22],
whereas autotaxin-dependent motility is blocked in LPA-1
deﬁcient ﬁbroblasts [23].
Previously, we have shown that LPA causes dispersal
of epithelial cell colonies [24]. Our report demonstrated2 Journal of Oncology
stepwiseupregulationofcellmotility featuresaftertreatment
of A431 cells with LPA. Speciﬁcally, we noted the following
changes: stimulation of lamellipodia formation, downreg-
ulation of cell-cell adhesion, and enhanced migration of
the cells. In continuing this line of research, we have thus
hypothesized that LPA changes cell motility by somehow
aﬀecting the cell microenvironment. To begin to test this
hypothesis, in this study we performed microarray analysis
of A431 cancer cells treated with LPA or PBS (for control)
to examine the changes in microenvironment-related genes.
Interestingly, microarray results revealed that LPA upregu-
lates several TGF-β1 target genes along with Ln-322, a major
component of basement membrane. Several independent
approaches also supported this ﬁnding.
2.MaterialsandMethods
2.1. Reagents. L-α-lysophosphatidic acid (oleoyl, LPA 18:1)
was purchased from Avanti Polar Lipids (Alabaster, AL)
and stored at −80
◦C. Polyclonal antibody (pAb) against
phosphorylated Smad2 (Ser465/467), GAPDH, and mon-
oclonal antibody (mAb) against Smad2/3 were purchased
from Cell Signaling Technology (Danvers, MA), BD Bio-
sciences (San Jose, CA), and Invitrogen (Carlsbad, CA),
respectively. BM165 (mAb against human laminin α3 chain)
was purchased from Life Technology Invitrogen (Carlsbad,
CA). H-300 (pAb against human laminin β3 chain) was
purchasedfromSantaCruzBiotechnology(SantaCruz,CA).
2778, pAb against laminin γ2 chain was prepared in-house,
as previously described in [25, 26]. MAb against β-actin was
purchased from Sigma (St. Louis, MO). Anti-rabbit IgG or
mouse IgG HRP-conjugated antibody was purchased from
GE health care (Pittsburgh, PA).
2.2. Cell Culture. A431, a human epidermal squamous
carcinoma cell line, was obtained from American Type
Culture Collection (Manassas, VA), maintained in DMEM
(Invitrogen), supplemented with 10% fetal bovine serum
(FBS; Invitrogen) and 2mM L-glutamine, and kept in
constant culture in a humidiﬁed incubator with 5% CO2 at
37
◦C.
2.3. Immunoblot Analysis. To examine phosphorylation of
Smad2 and expression of Ln-332 chains by LPA, A431 cells
were serum starved for 24h and incubated with PBS or LPA
(1–4μM) for indicated periods of time. Cells were lysed and
100μg of proteins were separated on 4–12% NuPAGE (Bis-
Tris) gels under reducing conditions. 3T3NIH cell lysates
were purchased from Cell Signaling and used as a positive
control (for Smad2 phosphorylation). After separation, the
same gel was transferred to a PVDF membrane and blocked
with 5% skim milk in 1X TBS and 0.1%Tween 20. After the
blocking step, pAb against phosphorylated Smad2 (pSmad2;
Ser465/467),GAPDH,ormAbagainstSmad2/3wasaddedat
the diluted ratio of 1:1000 and incubated at 4◦C overnight.
To check the expression of laminin α3, β3, and γ2 chains,
BM165 mAb, H-300pAb, or 2778pAb was added at the
diluted ratio of 1:1000, 1:200, 1:2000, respectively. MAb
against β-actin was used as an internal control at the diluted
Table 1: Primers used for quantitative RT-PCR. For RT-PCR, we
analyzedsamplesonanMiQmachineusingaFastStartSYBRGreen
Master Mix, with the following primer sets.
Gene Primer set Gene accession
number
LAMA3 5 -GGCTCACTCTGTATTGTTGG
NM 000227
5 -ACAGAGACTGCTTTGGTGTG
LAMB3 5 -TGATGGACAGGATGAAAGAC
NM 000228
5 -GGAAGCTGTAGCATCACTTG
LAMC2 5 -GAAGCCCAGAAGGTTGATAC
NM 005562
5 -GTGAGTGTTCTGGAGCAAAG
GAPDH 5 -ATGACATCAAGAAGGTGGTG
NM 002046
5 -CTGTAGCCAAATTCGTTGTC
PPIA 5 -CAAATGCTGGACCCAACACA
NM 021130
5 -TGCCATCCAACCACTCAGTC
ratio of 1:10000. Anti-rabbit IgG or mouse IgG HRP-
conjugated antibody was used as a secondary antibody at
the diluted ratio of 1:1000 for 1hr at room temperature.
The bands in all blots were visualized and imaged with
an ECL plus system (Perkin Elmer, Waltham, MA). Band
densities were quantiﬁed using ImageJ.D i ﬀerences were
examined with Student’s t-test statistics using SPSS, version
17 (Chicago, IL), with P values less than .05 accepted as
signiﬁcant.
2.4. RNA Extraction and cDNA Synthesis. To detect the
expression level of laminin α3, β3, and γ2 chains in
A431 cells, total RNA was isolated from cells treated with
PBS or 1-2μM( 1 μM for microarray analysis and 2μM
for real-time PCR) LPA using an RNAeasy kit (Qiagen,
Germantown, MD). Total RNA digested with RQ RNase-
free DNase I (Promega, Madison, WI) and OligoT primer
(Roche, Madison, WI) was incubated for 10 min at 70
◦C,
chilled on ice, and added to a 20ml aliquot of a reaction
mixture containing 4μl of Transcriptor RT reaction buﬀer
(Roche), 1μl of 10mM mixture of four dNTPs, and 1μl
of RNasin (Promega). In addition, 0.5μl of Transcriptor
Reverse Transcriptase (Roche, Madison, WI) was added and
incubation continued for 1h at 55
◦C. To stop the reaction,
the reaction mixture was heated for 5min at 85
◦C and then
chilled on ice. To remove RNA contamination in the reaction
mixture, RNase H (Promega) was added and incubated
for 30min at 37
◦C. RNA integrity was determined by
electrophoresis on a 1% agarose gel followed by visualization
of intact 18S and 28S ribosomal RNA bands. RNA purity
was measured using the A260/A280 ratio. To ensure that
the optical density at A260 was in the linear range, various
concentrations of RNA were plotted against absorbance.
2.5. cDNA Microarray Analysis. Microarray experiments
were performed by the Vanderbilt University Medical Center
Microarray Core using Aﬀymetrix Human U133 plus 2.0
chips according to manufacturer’s instructions. Data were
normalized using the Microarray Suite 5.0 algorithm. Due
to our interest in particular genes, only some probe sets were
analyzed, as shown in Table 1.Journal of Oncology 3
Comparisons were made between RNA extracted from
PBS-treated A431 cells and LPA-treated A431 cells (N = 2,
intriplicate).DiﬀerenceswereexaminedwithStudent’st-test
statistics using SPSS, version 17 (Chicago, IL), with P values
less than .05 accepted as signiﬁcant.
2.6. Quantitative Real-Time PCR (RT-PCR). For RT-PCR,
we analyzed samples on a MiQ machine (Bio-Rad Labora-
tories, Hercules, CA) using a FastStart SYBR Green Master
Mix (Roche, Madison, WI). The following primer sets were
used, as shown in Table 1: LAMA3 (forward): 5 -GGCTCA-
CTCTGTATTGTTGG, LAMA3 (reverse): 5 -ACAGAG-
ACTGCTTTGGTGTG, LAMB3 (forward): 5 -TGATGG-
ACAGGATGAAAGAC, LAMB3 (reverse): 5 -GGAAGC-
TGTAGCATCACTTG, LAMC2 (forward): 5 -GAAGCC-
CAGAAGGTTGATAC, LAMC2 (reverse): 5 -GTGAGT-
GTTCTGGAGCAAAG, GAPDH (forward): 5 -ATGACA-
TCAAGAAGGTGGTG, GAPDH (reverse): 5 -CTGTAG-
CCAAATTCGTTGTC. PPIA (forward): 5 -CAAATGCTG-
GACCCAACACA, PPIA (reverse): 5 -TGCCATCCAACC-
ACTCAGTC. These primers were designed by open-source
Primer3 software (http://primer3.sourceforge.net).
Comparisons were made between RNA extracted from
PBS-treated A431 cells and LPA-treated A431 cells (N = 2,
in duplicate or triplicate). Diﬀerences were examined with
Student’s t-test statistics using SPSS, version 17 (Chicago,
IL), with P values less than .05 accepted as signiﬁcant.
2.7. Cell Dispersal Assays. For dispersal assays, A431 cells
were seeded at a density of 104 cells/ml in 6-well plates
and allowed to grow for 24 h. After formation of colonies,
c e l l sw e r ec u l t u r e di ns e r u m - f r e eD M E Mf o r2 4ha n dt h e n
treated with PBS or LPA for 4 h. Microscopy was conducted
usingaZeissAxiovert200Mmicroscope(Zeiss,Thornwood,
NY) equipped with a temperature- and CO2-controlled
chamber (5 images per well, triplicate wells per treatment).
Microscopy was under the control of OpenLab software
(Improvision, Lexington, MA). To quantify cell behavior, we
manuallycountedboththenumberofdispersedcoloniesand
total colonies in each well of microplates. Diﬀerences were
examined using two-way ANOVA with Bonferroni posttest
using GraphPad Prism5 (La Jolla, CA), with values less
than .05 accepted as signiﬁcant. Data are presented as the
mean ± standard deviation ratio (percentage) of dispersed
colonies to total number of colonies imaged.
3. Results andDiscussion
We previously reported that LPA dramatically induces A431
squamous carcinoma cell colony dispersal, accompanied by
disruption of cell-cell contacts and individual cell migration
[24]. Herein, we analyzed gene expression of A431 cancer
cells treated with LPA in order to better understand how
LPA functions during cell colony dispersal. To this end, we
ﬁrst recapitulated experiments from our previous studies,
whereas A431 cells were serum starved for 24h and then
treated with LPA (1 μM) or PBS (for control) for 12 h. After
incubation, A431 cells were collected, and total RNA was
PBS LAP (2 μM)
28S
18S
Figure 1: RNA preparation. A431 cells were incubated for 24h in
serum-deprived culture medium. LPA (2μM) or PBS (control) was
added to medium and incubated for 12h at 37
◦C in a humidiﬁed,
5% CO2, 95% air atmosphere. Total RNA was isolated from
A431 cells treated with PBS or LPA (2μM) for 12 hrs, using a
Qiagen RNeasy kit. The RNA integrity was measured by the RNA
integrity number (RIN) software algorithm designed to classify
the eukaryotic total RNA, based on numbering from 1 to 10 (1
indicates the most degraded RNA proﬁle, and 10 indicates the
most intact RNA). Electrophoresis of RNA in eukaryote total RNA
Nano DE114000902 resulted in an RNA integrity number (RIN) of
10.
extracted for cDNA microarray analysis. The RNA integrity
was measured by the RNA integrity number (RIN) software
algorithm designed to classify the eukaryotic total RNA,
based on numbering from 1 to 10 (1 indicates the most
degraded RNA proﬁle, 10 indicates the most intact RNA).
The RNA integrity number was checked by electrophoresis
of RNA in Eukaryote Total RNA Nano DE114000902. The
RIN results of total RNA treated with PBS or LPA showed
the number of 10, showing that both RNA samples are intact
RNA (Figure 1 ).
Aﬀymetrix cDNA microarray analysis was then per-
formed to compare gene expression of A431cells treated
with either LPA or PBS. Due to our interest in particular
genes, only some probe sets were processed and analyzed
for this study. Of note, laminin α3( L A M A 3 ) ,β3( L A M B 3 ) ,
and γ2 chains (LAMC2), all components of the Ln-332
heterotrimer, were signiﬁcantly upregulated in LPA-treated
samples (Figure 2; N = 2, in duplicate or triplicate; P = .022,
.001, and .019, resp.). These results also revealed that
several other genes involved in extracellular matrix were
overexpressed in LPA-treated samples, including tenascin
C, cysteine rich protein 61, thrombospondin-1, and serine
peptidase inhibitor or plasminogen activator inhibitor-1
(data not shown). Interestingly, all of these genes have been
shown to be TGF-β1t a r g e tg e n e s[ 27–31].
The original observation on A431 colony dispersal has
led us to further investigate cell phenotype epithelial-to-
mesenchymal transition (EMT), which is reportedly induced
by TGF-β1 in some cell systems and shows a disconnect
between cells and dramatic changes in gene expression [32,
33]. TGF-β1 is a protein that controls cell proliferation and
growth in many cells, stimulates production of extracellular
matrix proteins, and induces EMT, which is accompanied4 Journal of Oncology
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Figure 2: cDNA microarray analysis. Microarray analysis was per-
formed on PBS and LPA-treated samples using Aﬀymetrix Human
U133 plus 2.0 chips according to manufacturer’s instructions, and
data were normalized using the Microarray Suite 5.0 algorithm.
Among the upregulated genes induced by LPA, all three subchains
of the intact Ln-332 molecule: α3 chain (LAMA3), laminin β3
(LAMB3), and laminin γ2 chain (LAMC2) were signiﬁcantly
increased.
by the decrease of cell-cell contacts and the increase of cell
motility [24]. TGF-β1 is known to bind and activate TGF-β1
t y p eIr e c e p t o r( T G F βR1), which phosphorylates receptor-
regulated Smad (R-Smad), Smad2, and Smad3 [34]. Phos-
phorylatedSmad2/3interactswithSmad4toformcomplexes
that translocate into cell nuclei, which leads to regulation of
geneexpression,eithernegativelyorpositively[34].Recently,
there were several reports suggesting the crosstalk between
GPCR activated by LPA or sphingosine 1-phosphate and
TGFβ signaling. For example, in keratinocytes, it has been
reported that LPA induces TGF-β1 signaling to mediate
growth arrest and chemotaxis [35]. Therefore, we performed
western blot analysis to determine whether LPA induces
the phosphorylation of Smad2 in A431 cells, using an anti-
phospho-Smad2 antibody (3A). These results showed that,
in contrast to the PBS control, LPA induced phosphorylation
of Smad2 in A431 cells, although, of the concentrations we
tested, only the highest dose, 4μM, signiﬁcantly enhanced
phosphorylation (Figure 3(b)). Our results are in line with
previous studies by Jeon et al. [36], which demonstrated that
Smad2/3 is phosphorylated upon LPA stimulation and that
it can be blocked using an LPA antagonist Ki16425. These
ﬁndings suggest that LPA may also induce TGF-β1 signaling
in A431 cells.
Among the overexpressed genes induced by LPA, we
further investigated the three subcomponents of the intact
Ln-332 molecule: α3 chain, β3, and γ2 chains. Ln-332 is
majorbasementmembraneglycoproteinexpressedmainlyin
epithelial cells that consists of these three chains in the form
p-Smad2
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Figure 3: LPA induces phosphorylation of Smad-2 during A431
colony dispersal. A431 cells were serum starved for 24 h and
incubated with PBS or LPA (1, 2, or 4 μM) for 1 h. (a, b)
Cells were lysed and 100μg of total proteins were separated on
4–12% NuPAGE gels under reducing conditions. 3T3NIH cell
lysate after TGF-β1 treatment was used as a positive control for
phosphorylation of Smad2. After separation, the same gel was
transferred to a PVDF membrane and blocked with 5% skim milk
in 1X TBS and 0.1% Tween 20. After blocking, a pAb against
phosphorylated Smad2 (p-Smad2; Ser465/467), a mAb against
Smad2/3, or GADPH was added at the diluted ratio of 1:1000 and
incubated at 4◦C overnight. Anti-rabbit IgG or mouse IgG HRP-
conjugated antibody was used as a secondary antibody at a diluted
ratioof1:1000.ThebandswerevisualizedwithanECLplussystem.
Protein expression levels were quantiﬁed from the western blots
using ImageJ. Results showed that 4μM LPA treatment for 12 h
signiﬁcantlyenhancedpSmad2proteinexpressioncomparedtoPBS
treatment (N = 3; P = .003).
of heterotrimer α3β3γ2 [36, 37]. Ln-332 plays a signiﬁcant
role in controlling cell behavior, such as cell adhesion,
migration, and spreading via cell surface receptors, including
integrin α3β1 and integrin α6β4[ 37, 38]. We performed
quantitative RT-PCR analysis using laminin primer sets
shown in Table 1 to conﬁrm the upregulation of the three
laminin genes upon LPA treatment of A431 cells,. Real-
time PCR analysis showed that LPA somewhat increased
the expression of laminin α3, β3, and γ2 chains in A431
cells (by ∼2–2.5-fold compared to PBS controls), although
not signiﬁcantly (N = 3; P = .11, .08, and .13, resp.),Journal of Oncology 5
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Figure 4: RT-PCR analysis of mRNA expression of laminin α3, β3,
and γ2 genes in LPA-treated A431 cells. To conﬁrm the results of the
previouslyperformedmicroarrays,RT-PCRanalysiswasperformed
as described in Section 2. Brieﬂy, A431 cells were treated with PBS
or 2μM LPA for 12 h, total RNA was extracted for each sample, and
cDNA was synthesized using reverse transcriptase. Samples were
analyzed on a MiQ machine using FastStart SYBR Green Master
Mix. The primer sets used are shown in Table 1.R e s u l t ss h o w e d
that LPA treatment increased Ln-332 component, α3, β3, and γ2,
expression (by ∼2–2.5-fold), although results were not determined
to be signiﬁcantly diﬀerent than PBS control treatments (N = 3;
P = .11, .08, and .13, resp.).
suggesting that LPA may also induce laminin α3, β3, and
γ2 gene expression at the mRNA level (Figure 4). However,
additional studies are needed to conﬁrm this ﬁnding.
Furthermore, western blot analysis using antibodies
against individual laminin α3, β3, and γ2 chains also
showed that protein expression increased after LPA treating
of A431 cells. Ln-332 α3a n dβ3 chains were signiﬁcantly
enhanced in LPA-treated cells, whereas γ2 chain was only
somewhat increased using this method (Figures 5(a) and
5(b)). Collectively, these results suggest that Ln-332 het-
erotrimer expression is also elevated after LPA treatment.
Interestingly, various cytokines, growth factors, and LPA
have previously been shown to promote the synthesis of
Ln-332 in human keratinocytes [39]. Taken together, three
independentapproachesshowthatLn-332isenhancedatthe
cDNA, mRNA, and protein levels, respectively.
The binding and their role of Ln-332 and integrin
receptorshavebeenintenselystudiedinvariousphysiological
events [43]. Ln-332 can promote strong cell adhesion
by interacting with α6β4 and intermediate ﬁlaments to
form hemidesmosomes [37, 44–46] or can behave as a
promigratory agent by binding to α3β1[ 47, 48]. These
functions are observed in normal skin and wound healing,
respectively [37, 44, 45, 48]. Collectively, these ﬁndings
lead us to believe that LPA-inducible Ln-332 promotes
A431 cell colony dispersal, presumably by interaction with
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Figure 5: LPA enhances laminin-332 protein expression in A431
cells. To examine the expression level of Ln-332 chains in LPA-
treated A431 cells, cells were serum starved for 24 h and incubated
with PBS or 2μML P Af o r1 2h .( a ,b )C e l l sw e r et h e nl y s e da n d
100 μg of proteins were separated on an 8% gel under reducing
conditions.Afterseparation,thesamegelwastransferredtoaPVDF
membrane and blocked with 5% skim milk in 1X TBS and 0.1%
Tween 20. After blocking, BM165 (mAb against human laminin
α3 chain) H-300 (pAb against human laminin β3 chain), a pAb
againstratlamininγ2chain,oramAbagainstactinwasaddedatthe
diluted ratios of 1:1000, 1:200, 1:2000, and 1:10000, respectively,
and incubated at 4◦C overnight. Anti-rabbit IgG or mouse IgG
HRP-conjugated antibody was used as a secondary antibody at the
diluted ratio of 1:1000. The bands were visualized with an ECL
plussystem(PerkinElmer,Waltham,MA).Proteinexpressionlevels
were quantiﬁed using ImageJ. Results showed that LPA treatment
consistently increased Ln-332 component expression. Both the Ln-
332 α3a n dβ3 chains were determined to be signiﬁcantly increased
(N = 3, P = .004), whereas the γ2chain was only somewhat elevated
compared to the PBS control treatment.
cell surface receptor integrins α3β1o rα6β4. While the
experimentation necessary to unravel this hypothesis is still
in early stages, we have obtained some data that supports
this idea. Using cell colony dispersal assays similar to our
previous studies [24], we have found that adding anti-Ln-
332 antibody to A431 cells almost completely blocked the
dispersal of LPA-treated colonies (Figures 6(a) and 6(b)).
T h e s er e s u l t ss t r o n g l ys u p p o r tag e n e r a lr o l ef o rL n - 3 3 2i n6 Journal of Oncology
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Figure 6: Anti-Ln-332 antibody prevents A431 colony from dispersing by LPA treatment. Cell colony dispersal assays were performed similarly
to our previous studies (serum-starved A431 cells for 24 h, treated with 2 μM LPA), with the addition of an anti-Ln-332 antibody (BM165).
(a, b) We found that anti-Ln-332 antibody signiﬁcantly blocked dispersal of LPA-treated colonies, compared to those colonies treated with
LPA alone (N = 3; P < .05). LPA-treated A431 colony dispersal percentages in the absence (LPA) or presence of BM165 antibody (LPA+anti-
Ln-332) are indicated as light-grey triangles or cross, respectively. These results strongly support a general role for Ln-332 in regulating the
“LPA eﬀect”. ∗P < .05, Two-way ANOVA (Bonferroni post test).
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Figure 7: Hypothetical working model of LPA-induced A431 colony dispersal. We hypothesize that LPA induces Ln-332 expression via TGF-β1
pathway. In our working model, LPA binds to LPA receptors on the A431 cell surface and transactivates TGF-β1t y p eIr e c e p t o r( T G F βR1),
which phosphorylates receptor-regulated Smad (R-Smad), Smad2, and Smad3. These results are supported by other previous ﬁndings [36,
40,41].AnotherpotentialpathwaymayleadtothedirectinductionofphosphorylationofSmad2/3.PhosphorylatedSmad2/3formscomplex
with Smad4 and translocates into the nucleus [41]. Smad4 functions as a positive transcriptional regulator of Ln-332 [42]. Finally, LPA
enhances Ln-332 expression to promote A431 colony dispersal.
regulating the “LPA eﬀect”. In addition, preliminary studies
have also shown that blocking antibodies against integrins
α3o rβ1, but not α6, remarkably reduced LPA-treated A431
colony dispersal (data not shown). Our ﬁndings are in line
with previous studies by Salo et al. [49], which showed
that antibodies blocking Ln-332 inhibit cell adhesion and
migration, subsequently leading to reduced tumor growth
and invasion in vivo. However, we plan to tackle additional
studies in the future to further investigate the speciﬁc role
of LPA in these data. Of note, Giannelli et al. previously
demonstrated that Ln-332 and TGF-β1 cooperatively induce
EMT in hepatocellular carcinoma [50].
In summary, we propose a working model of LPA-
induced A431 colony dispersal (Figure 7). We hypothesizeJournal of Oncology 7
that LPA induces Ln-332 expression via the TGF-β1p a t h w a y .
In our working model, LPA binds to LPA receptors on the
A431 cell surface and transactivates TGF-β1t y p eIr e c e p t o r
(TGFβR1), which phosphorylates receptor-regulated Smad
(R-Smad), Smad2, and Smad3 [36]. In addition, LPA
potentially induces the direct phosphorylation of Smad2/3
via LPA receptors, or LPA-induced TGF-β1 signals activate
phosphorylation of Smad2/3.
Phosphorylated Smad2/3 forms complex with Smad4
and translocates into the nucleus. It has been reported that
smad4functionsasapositivetranscriptionalregulatorofLn-
332 in colorectal cancer cell lines [42]. Through these poten-
tial pathways, LPA potentially enhances Ln-332 expression,
leading to the promotion of A431 colony dispersal.
However, we recognize that our results could be the
consequences of the activation of other pathways than
TGF-β. In brief, we acknowledge that many previous studies
have explored the downstream eﬀectors of LPA, including
RhoA, which is involved in contraction and cell rounding,
Rac, which is involved in cell spreading and migration,
Akt, which is involved in cell survival, and RAS, which
is important in DNA synthesis and viability [51]. These
multiple eﬀects may explain why one compound, LPA, could
have such a repertoire of cell responses.
4. Conclusions
Herein, we have reported that LPA induces TGF-β1t a r g e t
gene expression including Ln-332 during LPA-induced A431
colony dispersal, and we conclude that Ln-332 plays a
signiﬁcant role in promoting colony dispersal and single-cell
migration, at least for the A431 cell line.
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